Click the Why column to see why an item matched the search.
| Match | Type | Why |
|---|
| Therapeutic fetal-globin inducers reduce transcriptional repression in hemoglobinopathy erythroid progenitors through distinct mechanisms. | Academic Article |
Why?
|
| BCL11A is a major HbF quantitative trait locus in three different populations with beta-hemoglobinopathies. | Academic Article |
Why?
|
| Butyrate treatment in beta-hemoglobinopathies. | Academic Article |
Why?
|
| Butyrate-induced reactivation of the fetal globin genes: a molecular treatment for the beta-hemoglobinopathies. | Academic Article |
Why?
|
| Carrier detection and prenatal diagnosis of hemoglobinopathies in Ontario. | Academic Article |
Why?
|
| DNA diagnosis for the detection of sickle hemoglobinopathies. | Academic Article |
Why?
|
| Fetal hemoglobin in ß hemoglobinopathies: Is enough too much? | Academic Article |
Why?
|
| Good practice guidelines for laboratory investigation of hemoglobinopathies. | Academic Article |
Why?
|
| Prenatal diagnosis of hemoglobinopathies in Ontario, Canada. | Academic Article |
Why?
|
| Prospects of gene therapy for hemoglobinopathies. | Academic Article |
Why?
|
| Strategies to improve pharmacogenomic-guided treatment options for patients with ß-hemoglobinopathies. | Academic Article |
Why?
|
| Targeted fetal hemoglobin induction for treatment of beta hemoglobinopathies. | Academic Article |
Why?
|
| Targeting fetal hemoglobin expression to treat ß hemoglobinopathies. | Academic Article |
Why?
|
| The interactions of alpha-thalassemia with hemoglobinopathies. | Academic Article |
Why?
|
| Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach. | Academic Article |
Why?
|